275 related articles for article (PubMed ID: 30672125)
21. Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells.
Belluti S; Basile V; Benatti P; Ferrari E; Marverti G; Imbriano C
Cell Death Dis; 2013 Aug; 4(8):e756. PubMed ID: 23928695
[TBL] [Abstract][Full Text] [Related]
22. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
24. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
25. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing TOP2A mRNA.
Cui S; Li F
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34414458
[TBL] [Abstract][Full Text] [Related]
26. p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication.
Yeo CQX; Alexander I; Lin Z; Lim S; Aning OA; Kumar R; Sangthongpitag K; Pendharkar V; Ho VHB; Cheok CF
Cell Rep; 2016 Apr; 15(1):132-146. PubMed ID: 27052176
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract][Full Text] [Related]
29. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.
Mancini F; Di Conza G; Pellegrino M; Rinaldo C; Prodosmo A; Giglio S; D'Agnano I; Florenzano F; Felicioni L; Buttitta F; Marchetti A; Sacchi A; Pontecorvi A; Soddu S; Moretti F
EMBO J; 2009 Jul; 28(13):1926-39. PubMed ID: 19521340
[TBL] [Abstract][Full Text] [Related]
30. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
31. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
32. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
Wang X; Zhu J
Thorac Cancer; 2018 Jun; 9(6):676-683. PubMed ID: 29697201
[TBL] [Abstract][Full Text] [Related]
33. MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4.
Wang Q; Selth LA; Callen DF
Oncotarget; 2017 May; 8(18):29914-29924. PubMed ID: 28430625
[TBL] [Abstract][Full Text] [Related]
34. TOPBP1 recruits TOP2A to ultra-fine anaphase bridges to aid in their resolution.
Broderick R; Nieminuszczy J; Blackford AN; Winczura A; Niedzwiedz W
Nat Commun; 2015 Mar; 6():6572. PubMed ID: 25762097
[TBL] [Abstract][Full Text] [Related]
35. TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway.
Pei YF; Yin XM; Liu XQ
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):197-207. PubMed ID: 29045811
[TBL] [Abstract][Full Text] [Related]
36. PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.
Takihira S; Yamada D; Osone T; Takao T; Sakaguchi M; Hakozaki M; Itano T; Nakata E; Fujiwara T; Kunisada T; Ozaki T; Takarada T
Br J Cancer; 2024 May; 130(9):1493-1504. PubMed ID: 38448751
[TBL] [Abstract][Full Text] [Related]
37. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
[TBL] [Abstract][Full Text] [Related]
38. Neochlorogenic acid enhances the antitumor effects of pingyangmycin via regulating TOP2A.
Che J; Zhao T; Liu W; Chen S; Yang G; Li X; Liu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355372
[TBL] [Abstract][Full Text] [Related]
39. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
40. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
